AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Merus(MRUS) saw insider trading activity on 12/18/2025, there were 2 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 12/18/2025 | -- | GENMAB A/S | Buy | 271547 | 97.00 | 26340.06k |
| 12/12/2025 | -- | Iwicki Mark T | Sell | 73576 | 97.00 | 7136.87k |
| 12/12/2025 | VP Controller, PAO | Shuman Harry | Sell | 11002 | 97.00 | 1067.19k |
| 12/12/2025 | President, CEO & PEO | Lundberg Sven Ante | Sell | 83435 | 97.00 | 8093.2k |
| 12/10/2025 | VP Controller, PAO | Shuman Harry | Buy | 800 | 18.61 | 14.89k |
| 12/10/2025 | VP Controller, PAO | Shuman Harry | Sell | 1700 | 96.10 | 163.37k |
| 12/10/2025 | VP Controller, PAO | Shuman Harry | Buy | 900 | 24.43 | 21.99k |
| 11/28/2025 | VP Controller, PAO | Shuman Harry | Sell | 8300 | 95.92 | 796.14k |
| 7/18/2025 | COO & GC | Silverman Peter B. | Sell | 25000 | 60.00 | 1500.0k |
| 7/18/2025 | COO & GC | Silverman Peter B. | Buy | 25000 | 24.43 | 610.75k |
[Company Profile]
Merus N.V. was incorporated under the laws of the Netherlands on June 16, 2003.The company is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics. Their pipeline of full-length human bispecific antibody candidates, which they refer to as Biclonics, are generated from their technology platform.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet